Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques

BACKGROUND: Tecovirimat (ST-246) is being developed as an antiviral therapeutic for smallpox for use in the event of an accidental or intentional release. The last reported case of smallpox was 1978 but the potential for use of variola virus for biowarfare has renewed interest in smallpox antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Andrew T, Grosenbach, Douglas W, Brasel, Trevor L, Baker, Robert O, Cawthon, Andrew G, Reynolds, Erin, Bailey, Tara, Kuehl, Philip J, Sugita, Victoria, Agans, Krystle, Hruby, Dennis E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151088/
https://www.ncbi.nlm.nih.gov/pubmed/29982575
http://dx.doi.org/10.1093/infdis/jiy326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151088/
https://www.ncbi.nlm.nih.gov/pubmed/29982575
http://dx.doi.org/10.1093/infdis/jiy326

Ejemplares similares